Levobunolol_hydrochloride_SDS_MedChemExpress

合集下载

盐酸度洛西汀欧洲药典

盐酸度洛西汀欧洲药典

Duloxetine Hydrochloride(doo lox' e teen hye'' droe klor' ide).C18H19NOS ·HCl 333.882-Thiophenepropanamine, N-methyl--(1-naphthalenyloxy)-, hydrochloride, (S)-; (+)-(S)-N-Methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride[136434-34-9].DEFINITIONDuloxetine Hydrochloride contains NLT 97.0% and NMT 102.0% of C18H19NOS ·HCl, calculated on the dried basis.IDENTIFICATIONChange to read:• A. Infrared Absorption 197K (ERR 1-Jul-2012)• B. The retention time of the major peak in the Sample solution correspondsto that of the duloxetine S-isomer from the System suitability solution in the test for Limit of Duloxetine Related Compound A.Change to read:• C. Identification Tests —General, Chloride 191Sample solution: 5 mg/mL in methanolAcceptance criteria: Meets the requirements (ERR 1-Jul-2012)ASSAY• ProcedureProtect solutions of duloxetine from light.Buffer: 2.9 g/L of phosphoric acid in water. Adjust with sodium hydroxide solution to a pH of 2.5. To each L of this solution add 10.3 g of sodium 1-hexanesulfonate monohydrate, and dissolve.Mobile phase: Acetonitrile, n-propanol, and Buffer (13:17:70)Diluent: Acetonitrile and water (25:75)ClickSystem suitability solution: 0.2 mg/mL of USP Duloxetine Hydrochloride RS in Mobile phase. Heat the solution to at least 40for a minimum of 1 h.[Note —The resulting solution contains duloxetine impurity B, duloxetine impurity C, duloxetine impurity D, duloxetine impurity E, and duloxetine related compound F. ] Standard solution: 0.1 mg/mL of USP Duloxetine Hydrochloride RS in DiluentSample solution: 0.1 mg/mL of Duloxetine Hydrochloride in DiluentChromatographic system(See Chromatography 621, System Suitability .)Mode: LCDetector: UV 230 nmColumn: 4.6-mm × 15-cm; 3.5-µm packing L7Column temperature: 40 ± 3Flow rate: 1 mL/minInjection size: 10 µLRun time: 2 times the retention time of duloxetineSystem suitabilitySample: System suitability solution[Note —See Table 1 for relative retention times. ]Suitability requirements Resolution: NLT 1.5 between duloxetine and duloxetine relatedcompound F peaksTailing factor: NMT 1.5 for the duloxetine peakRelative standard deviation: NMT 1.0% for the duloxetine peakAnalysisSamples: Standard solution and Sample solutionCalculate the percentage of duloxetine hydrochloride (C18H19NOS ·HCl) in the portion of sample taken:Result = (rU/rS) × (CS/CU) × 100Acceptance criteria: 97.0%–102.0% on the dried basisIMPURITIES• Heavy Metals, Method II 231: NMT 10 ppm• Residue On Ignition281: NMT 0.2% rU =peak response from the SamplesolutionrS =peak response from the StandardsolutionCS =concentration of USP DuloxetineHydrochloride RS in the Standardsolution (mg/mL)CU =concentration of DuloxetineHydrochloride in the Sample solution(mg/mL)• Organic ImpuritiesProtect solutions of duloxetine from light.Buffer, Mobile phase, Diluent, and System suitability solution: Proceed as directed in the Assay.Sensitivity solution: 0.2 µg/mL of USP Duloxetine Hydrochloride RS in DiluentSample solution: 0.2 mg/mL of Duloxetine Hydrochloride in DiluentChromatographic system: Proceed as directed in the AssayRun time: 2.4 times the retention time of duloxetineSystem suitabilitySamples: System suitability solution and Sensitivity solution[Note —See Table 1 for relative retention times. ]Suitability requirementsResolution: NLT 1.5 between duloxetine impurity C and duloxetineimpurity D; NLT 1.5 between duloxetine and duloxetine relatedcompound F, System suitability solutionTailing factor: NMT 1.5 for the duloxetine peak, System suitabilitysolutionRelative standard deviation: NMT 1.0% for the duloxetine peak, System suitability solutionSignal-to-noise ratio: NLT 20 for the duloxetine peak, Sensitivity solution AnalysisSample: Sample solutionCalculate the percentage of any individual impurity in the portion ofDuloxetine Hydrochloride taken:Result = (rU/rT) × (1/F) × 100Acceptance criteria: See Table 1. Table 1 rU =peak response of each impurity fromthe Sample solutionrT =sum of the responses of all the peaksfrom the Sample solutionF =relative response factor (see Table 1)Name Relative Retention TmeRelative Response Factor AcceptanceCriteriaNMT (%)Duloxetine impurity B a ,g 0.150.36—Duloxetine impurity C b ,g0.43 1.0—Duloxetine impurity D c ,g0.48 1.8—Duloxetine impurity E d ,g0.74 1.0—Duloxetine 1.0——• Limit of Duloxetine Related Compound AMobile phase: Hexane and isopropyl alcohol (83:17). To 1 L of this mixture add 2 mL of diethylamine.System suitability solution: 0.1 mg/mL each of USP DuloxetineHydrochloride RS and USP Duloxetine Related Compound A RS inMobile phase. Sonication may be used to aid in dissolution.Sensitivity solution: 0.1 µg/mL of USP Duloxetine Hydrochloride RS in Mobile phaseSample solution: 0.1 mg/mL of Duloxetine Hydrochloride in Mobile phase.Sonication may be used to aid in dissolution.Chromatographic system (See Chromatography 621, System Suitability .)Mode: LCDetector: UV 230 nmColumn: 4.6-mm × 25-cm; 5-µm packing L40Column temperature: 40Flow rate: 1 mL/minInjection size: 10 µLRun time: 2 times the retention time of duloxetineSystem suitabilitySamples: Sensitivity solution and System suitability solution[Note —The relative retention times for duloxetine and duloxetine related compound A are 1.0 and 1.3, respectively. ]Suitability requirementsResolution: NLT 3.5 between duloxetine and duloxetine relatedcompound A, System suitability solutionTailing: Between 0.8 and 1.5 each for duloxetine and duloxetine related compound A peaks, System suitability solutionRelative standard deviation: NMT 5.0% for the duloxetine peak, System suitability solutionSignal-to-noise ratio: NLT 3, Sensitivity solutionAnalysisDuloxetine related compound F e 1.1 1.00.5Duloxetine impurity G f ,g 1.40.51—Any individual unspecified impurity — 1.00.1Total impurities——0.6a 3-(Methylamino)-1-(thiophen-2-yl)propan-1-ol.b 4-[3-(Methylamino)-1-(thiophen-2-yl)propyl]naphthalen-1-ol.c Naphthalen-1-ol.d 1-(3-(Methylamino)-1-(thiophen-2-yl)propyl)naphthalen-2-ol.e (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-3-yl)propan-1-amine.f 1-Fluoronaphthalene.g Controlled at Any individual unspecified impurity level.Sample: Sample solutionCalculate the percentage of duloxetine related compound A in the portion of Duloxetine Hydrochloride taken:Result = (rU/rT) × 100Acceptance criteria: NMT 0.5%SPECIFIC TESTS• Loss On Drying 731: Dry at 105 for 3 h: it loses NMT 0.5% of its weight. ADDITIONAL REQUIREMENTS• Packaging And Storage: Protect from light. Store at room temperature. • USP Reference Standards 11:USP Duloxetine Hydrochloride RSUSP Duloxetine Related Compound A RS(R)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride.C18H19NOS ·HCl 333.88Auxiliary Information — Please check for your question in the FAQs before contactingUSP. USP36–NF31 Page 3354Pharmacopeial Forum: Volume No. 37(4)Chromatographic Column —DULOXETINE HYDROCHLORIDEChromatographic columns text is not derived from, and not part of, USP 36 or NF 31.rU =peak response for duloxetine relatedcompound A from the SamplesolutionrT =sum of the responses of duloxetineand duloxetine related compound Apeaks from the Sample solutionTopic/Question Contact Expert CommitteeMonograph Heather R. Joyce, Ph.D. Associate Scientific Liaison1-301-918-8442(SM42010) Monographs - SmallMolecules 4Reference Standards RS Technical Services1-301-816-8129rstech@。

布罗佐喷钠 分子式

布罗佐喷钠 分子式

布罗佐喷钠分子式
布罗佐喷钠(Brozopine)是一种新型的药物,它被广泛用于治疗焦虑症和抑郁症等精神障碍。

它的分子式为C17H19FN4O2,具有独特的化学结构。

布罗佐喷钠的作用机制是通过调节神经递质的释放和再摄取来改善患者的心理状态。

它主要与脑内的多巴胺和血清素受体相互作用,从而调节神经传递的平衡。

这种药物具有较高的选择性和亲和力,可以减少副作用的发生。

临床研究表明,布罗佐喷钠在治疗焦虑症和抑郁症方面表现出良好的疗效。

它可以显著减少患者的焦虑和抑郁程度,改善其生活质量。

与传统的抗焦虑药物和抗抑郁药物相比,布罗佐喷钠不仅具有更好的疗效,还能减少因药物治疗而引起的不良反应。

除了治疗焦虑症和抑郁症,布罗佐喷钠还被用于其他精神障碍的治疗。

例如,临床研究表明,它对强迫症和创伤后应激障碍等疾病也具有一定的疗效。

然而,由于其作用机制尚不完全清楚,布罗佐喷钠在这些领域的应用仍需进一步的研究和探索。

总的来说,布罗佐喷钠是一种具有潜力的药物,可以有效治疗多种精神障碍。

它的分子式为C17H19FN4O2,通过调节神经递质的释放和再摄取来改善患者的心理状态。

尽管仍有许多问题需要解决,但布罗佐喷钠的疗效和安全性使其成为精神科医生的重要选择之一。

相信随着科学技术的不断进步,布罗佐喷钠将为更多患者带来希望和康复。

氢溴酸沃替西汀杂质的制备研究

氢溴酸沃替西汀杂质的制备研究

安徽医药Anhui Medical and Pharmaceutical Journal2020Jun,24(6)doi:10.3969/j.issn.1009⁃6469.2020.06.004◇药学研究◇氢溴酸沃替西汀杂质的制备研究年帅,黄美容,曹阳,黄顺旺,曹明成作者单位:合肥创新医药技术有限公司,安徽合肥230088通信作者:曹明成,男,主任中药师,研究方向为新药研究,E⁃mail:****************基金项目:合肥市关键技术研究重大专项(ZR201809200179)摘要:目的研究抗抑郁药物氢溴酸沃替西汀杂质,1,4⁃二(2⁃溴苯基)哌嗪和2⁃溴苯基哌嗪的合成;从而为该药原料及片剂的质量研究提供对照品。

方法以哌嗪为原料,与邻溴碘苯通过偶联反应得到两种氢溴酸沃替西汀杂质,并经过核磁共振氢谱(1H NMR)、质谱(MS)等进行了结构确证。

结果合成了氢溴酸沃替西汀两种杂质,纯度均在98.0%以上,为建立质量标准所需的对照品提供了参考。

结论合成氢溴酸沃替西汀杂质使用的各种原料经济易得,合成工艺简单,反应条件温和,反应操作简单,所得产品收率和纯度均较高,合成路线可行。

关键词:氢溴酸沃替西汀;分析样品制备方法;药物污染;化学技术,合成;杂质Study on the preparation of vortioxetine hydrobromide impurities NIAN Shuai,HUANG Meirong,CAO Yang,HUANG Shunwang,CAO Mingcheng Author Affiliation:Hefei Innovative Pharmaceutical Technology Co.,Ltd.,Hefei,Anhui230088,China Abstract:Objective To study the synthesis of1,4⁃bis(2⁃bromophenyl)piperazine and2⁃bromophenylpiperazine,impurities of the antidepressant vortioxetine hydrobromide.So as to provide a reference for the quality research of the raw materials and tablets. Methods Using piperazine as raw material,two impurities of vortioxetine hydrobromide were synthesized by coupling reaction with o⁃bromoiodobenzene,and their structures were confirmed by NMR hydrogen spectroscopy(1H NMR)and Mass spectrometry (MS).Results Two impurities of vortioxetine hydrobromide were synthesized,with a purity of move than98.0%,which provided a reference for the establishment of quality standards.Conclusion Various raw materials for the synthesis of vortioxetine hydrobro⁃mide impurities are economical and easy to obtain.The synthetic process is simple,the reaction conditions are mild,and the opera⁃tion is simple.The yield and purity of the product are high.The synthetic route is feasible.Key words:Vortioxetine hydrobromide;Analytic sample preparation methods;Drug contamination;Chemical techniques,syn⁃thetis;Impurity氢溴酸沃替西汀(Vortioxetine hydrobromide),化学名为1⁃[2⁃(2,4⁃二甲基⁃苯巯基)⁃苯基]⁃哌嗪氢溴酸盐,由日本武田药品工业株式会社和丹麦灵北制药有限公司联合研制,于2013年10月在欧洲上市,用于治疗成人重度抑郁症[1⁃7]。

EL-102_SDS_MedChemExpress

EL-102_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

安妥明的实验报告

安妥明的实验报告

一、实验目的1. 掌握安妥明的合成原理和方法。

2. 熟悉有机合成实验的基本操作步骤。

3. 提高实验操作技能,培养严谨的科学态度。

二、实验原理安妥明(Antipyrine)是一种常用的非甾体抗炎药,具有解热、镇痛、抗炎作用。

本实验采用对氯苯氧异丁酸与乙醇、盐酸反应制备安妥明。

三、实验材料与仪器1. 实验材料:对氯苯氧异丁酸、乙醇、盐酸、石油醚、甲苯、无水硫酸钠、无水碳酸钠、蒸馏水、氢氧化钠、碳酸氢钠。

2. 实验仪器:反应瓶、烧杯、玻璃棒、漏斗、滤纸、滤器、蒸发皿、电热套、冷凝管、回流冷凝管、液封装置、温度计、紫外灯。

四、实验步骤1. 对氯苯氧异丁酸的制备:将无水硫酸钠放入反应瓶中,加入对氯苯氧异丁酸,再加入无水碳酸钠。

将反应瓶置于电热套上,加热至100℃,回流反应2小时。

冷却后,将反应液倒入烧杯中,用滤纸过滤,滤液用无水碳酸钠中和至中性。

将中和后的溶液倒入烧杯中,加入无水硫酸钠,过滤,滤液用无水碳酸钠中和至中性。

将中和后的溶液倒入烧杯中,加入无水硫酸钠,过滤,滤液用无水碳酸钠中和至中性。

2. 安妥明的制备:将上述滤液倒入反应瓶中,加入乙醇和盐酸,加热至回流。

将反应瓶置于电热套上,回流反应2小时。

冷却后,将反应液倒入烧杯中,用滤纸过滤,滤液用氢氧化钠中和至中性。

将中和后的溶液倒入烧杯中,加入无水硫酸钠,过滤,滤液用氢氧化钠中和至中性。

3. 精制:将上述滤液倒入烧杯中,加入无水硫酸钠,过滤,滤液用无水碳酸钠中和至中性。

将中和后的溶液倒入烧杯中,加入无水硫酸钠,过滤,滤液用无水碳酸钠中和至中性。

4. 结晶:将上述滤液倒入烧杯中,加入无水硫酸钠,搅拌至结晶。

将结晶用滤纸过滤,滤液用无水碳酸钠中和至中性。

将中和后的溶液倒入烧杯中,加入无水硫酸钠,搅拌至结晶。

将结晶用滤纸过滤,滤液用无水碳酸钠中和至中性。

5. 干燥:将结晶用滤纸过滤,滤液用无水碳酸钠中和至中性。

将中和后的溶液倒入烧杯中,加入无水硫酸钠,搅拌至结晶。

核苷类药物知识

核苷类药物知识

核苷类药物知识核苷类药物的综述,免费下载的,大家给好评吧!O(∩_∩)O~1. 前言核苷和脱氧核苷是由核苷碱基分别和核糖或脱氧核糖以苷键形式而构成的,它们是组成核糖核酸(RNA)和脱氧核糖核酸(DNA)的基本元件,是遗传基因的基础。

核苷和脱氧核苷系列衍生物具有多种生物活性物质,可以直接或间接地作为药物使用,在治疗多种重大的疾病方面起到极其重要的作用,国外已经研究开发出系列化药物并商品化,国内研究与开发较晚,发展前景非常广阔.1。

1 核苷类药物的合成与生产从20世纪40年代末期,国外就开始核苷及其系列药物的合成与开发。

目前世界排名前25位制药大公司都有自己的核苷衍生物生产或加工厂,并且均有持有专利的核苷类药物上市,并且从20世纪90年代起投入巨资用于基因药物的研究。

据国外有关资料预计,2003年基因药物的市场价值将超过30亿美元.在亚洲,日本是最早开发核苷类药物和基因药物的国家,如武田、住友、味之素等公司均有相关的中间体开发机构和生产基地。

另外韩国、印度在20世纪90年代初开始投入这类产品的开发与生产.中国在核苷及其衍生物方面的开发研究与生产始于20世纪90年代末期,但是核苷及其中间体品种少,部分原料依赖进口,与目前快速发展的生命科学及相关药物研究不相适应。

1。

2 核苷类药物的应用核苷与脱氧核苷系列化合物主要用于医药领域,用途广泛,而且新产品层出不穷,应用范围不断扩大.(一)抗病毒药物。

核苷类抗病毒药物品种繁多,结构多样,主要以破坏病毒转录,干扰或终止病毒核酸的合成为目的,用于抗疱疹病毒、HIV、HBV、以及流感和呼吸系统病毒等DNA和RNA病毒。

目前在这方面应用最多,而且新出现的药物主要集中于治疗上述疾病。

(二)抗肿瘤药物。

目前用于临床和正在研究的核苷类抗肿瘤药物有数十种,它们的主要作用是干扰肿瘤的DNA合成,或者影响核酸的转录过程,抑制蛋白质的合成,从而达到治疗肿瘤的效果。

(三)抗真菌类药物.具有这方面作用的核苷类化合物已经有多种用于临床应用,其中有部分产品对多种真菌具有抑制作用,而且对哺乳动物几乎无毒性。

维莫非尼片说明书

维莫非尼片说明书

核准日期:2017年3月10日修改日期:2017年5月26日2017年11月29日2018年7月24日2020年2月13日2021年2月26日2022年1月17日2022年2月22日维莫非尼片说明书请仔细阅读说明书并在医师指导下使用【药品名称】通用名:维莫非尼片商品名:佐博伏®,英文商品名Zelboraf®英文名:Vemurafenib film-coated tablets汉语拼音:Weimofeini Pian【成份】本品主要活性成分为维莫非尼,以维莫非尼和琥珀酸醋酸羟丙甲纤维素固体分散体存在。

化学名称:丙烷-1-磺酸{3-[5-(4-氯苯基)-1H- 吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟代苯基}- 酰胺。

化学结构式:分子式:C23H18ClF2N3O3S分子量:489.93【性状】两面凸起、粉白色至橙白色的薄膜衣片。

【适应症】佐博伏®适用于治疗经CFDA批准的检测方法确定的BRAF V600突变阳性的不可切除或转移性黑色素瘤。

【规格】240 mg【用法用量】患者必须经由CFDA批准的检测方法确定的证明肿瘤为BRAF V600突变阳性,才可使用佐博伏®治疗。

佐博伏®不能用于BRAF野生型黑色素瘤患者。

首剂药物应在上午服用,第二剂应在此后约12小时,即晚上服用。

每次服药均可随餐或空腹服用。

用一杯水送服药物,服药时整片吞下佐博伏®片剂。

不应咀嚼或碾碎佐博伏®片剂。

标准剂量佐博伏®的推荐剂量为960 mg(四片240 mg片剂),每日两次。

治疗持续时间建议佐博伏®治疗应持续至疾病进展或发生不可接受的毒性反应(参见表1和表2)。

漏服如果漏服一剂计划的药物,可在下一剂服药4小时以前补服漏服的药物,以维持每日两次的给药方案。

不应同时服用两剂药物。

呕吐如果佐博伏®服药后发生呕吐,患者不应追加剂量,而应按常规剂量继续治疗。

阿拉丁癸二酸二丁酯产品安全技术说明书

阿拉丁癸二酸二丁酯产品安全技术说明书

GHS07:感叹号3成分/组成信息 3.1物 质分子式:C18H34O4; [-(CH2)4CO2(CH2)3CH3]2分子量 :314.46 g/mol成分 (单一物质)浓度癸二酸二丁酯Dibutyl sebacateCAS No. 109-43-3EC-编号203-672-598%4急救措施4.1必要的急救措施描述一般的建议请教医生。

出示此安全技术说明书给到现场的医生看。

如果吸入如果吸入,请将患者移到新鲜空气处。

如果停止了呼吸,给于人工呼吸。

请教医生。

在皮肤接触的情况下用肥皂和大量的水冲洗。

请教医生。

在眼睛接触的情况下用大量水彻底冲洗至少15分钟并请教医生。

如果误服切勿给失去知觉者从嘴里喂食任何东西。

用水漱口。

请教医生。

4.2最重要的症状和影响,急性的和滞后的据我们所知,此化学,物理和毒性性质尚未经完整的研究。

4.3及时的医疗处理和所需的特殊处理的说明和指示无数据资料5消防措施5.1灭火介质火灾特征无数据资料灭火方法及灭火剂用水雾,耐醇泡沫,干粉或二氧化碳灭火。

5.2源于此物质或混合物的特别的危害碳氧化物5.3救火人员的预防如必要的话,戴自给式呼吸器去救火。

5.4进一步的信息无数据资料6泄露应急处理6.1人员的预防,防护设备和紧急处理程序使用个人防护设备。

防止吸入蒸汽、气雾或气体。

保证充分的通风。

将人员撤离到安全区域。

6.2环境预防措施不要让产物进入下水道。

6.3抑制和清除溢出物的方法和材料用惰性吸附材料吸收并当作危险废品处理。

存放进适当的闭口容器中待处理。

6.4参考其他部分丢弃处理请参阅第13节。

7安全操作与储存7.1安全操作的注意事项避免接触皮肤和眼睛。

防止吸入蒸汽和烟雾。

一般性的防火保护措施。

7.2安全储存的条件,包括任何不兼容性贮存在阴凉处。

容器保持紧闭,储存在干燥通风处。

7.3特定用途无数据资料8接触控制/个体防护8.1控制参数最高容许浓度成分 CAS No. 值控制参数基准癸二酸二丁酯Dibutyl sebacate 109-43-3PC-TWA无数据资料 《工作场所有害因素职业接触限值》国家标准中的工作场所时间加权平均容许浓度无数据资料无数据资料 无数据资料8.2暴露控制适当的技术控制按照良好工业和安全规范操作。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Levobunolol (hydrochloride)Catalog No. :HY-B1035CAS No. :27912-14-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:l⁻Bunolol hydrochlorideFormula:C17H26ClNO3Molecular Weight:327.85CAS No. :27912-14-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

相关文档
最新文档